Echosens and health systems link up to build real-world evidence model for NASH care

hospital computer
The NASH Network represents a consortium of care providers, including Geisinger, Baylor College of Medicine, Mount Sinai School of Medicine and Ochsner Health System. (Pixabay)

Diagnostic device maker Echosens is teaming up with the NASH Network and the Kinetix Group to develop a real-world evidence framework to help standardize delivery and optimize care for patients with nonalcoholic steatohepatitis.

Also known as fatty liver disease, NASH is projected to grow into a more than $20 billion global market in the next few years—with demand for liver assessments and care standards being driven by the same forces making liver disease a highly competitive drug development pipeline.

In addition, the chronic, asymptomatic condition is set to become the leading cause of liver transplantation in the U.S., with the disease affecting one in three Americans.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Through a pilot study, the trio aims to evaluate an interdisciplinary model for health systems—engaging primary care physicians alongside hepatologists, endocrinologists and other specialists—to help identify at-risk patients earlier.

Paris-based Echosens markets FibroScan, a noninvasive device that quantitatively measures liver stiffness and fat using a gel probe, as well as the FibroMeter blood test, which checks for liver fibrosis and cirrhosis. The Kinetix Group consultancy firm focuses on helping life science companies integrate the use of real-world evidence, including working with health systems and payers to build value-based delivery models.

RELATED: France's Echosens reels in €30M for international expansion

Meanwhile, the NASH Network represents a consortium of health systems working to develop a set of best practices for NASH care, counting Geisinger, the Baylor College of Medicine, the Mount Sinai School of Medicine and Ochsner Health System as charter members.

“While a majority of patients with [non-alcoholic fatty liver disease] will not advance to liver fibrosis or cirrhosis, it is critical to develop effective and efficient models to identify the subset of NAFLD patients with NASH in the settings where they receive care,” said Douglas Dieterich, a professor of medicine in the division of liver diseases at Mount Sinai, in a statement.

RELATED: Philips gets FDA nod for noninvasive liver assessment

The NASH Network said it has partnered with academic medical centers that have expressed the importance of using Echosens’ FibroScan device as part of a standard workup to appropriately identify patients with progressive disease. A similar ultrasound device for assessing liver tissue stiffness developed by Philips received FDA clearance last year.

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.